The influence of antidepressant therapy on the level of brain-derived neurotrophic factor in the blood serum of patients with melancholic depression: a pilot study

The influence of antidepressant therapy on the level of brain-derived neurotrophic factor in the blood serum of patients with melancholic depression: a pilot study

 

Authors

 

M.G. Uzbekov

Moscow Research Institute of Psychiatry ‒ Branch of FSBI “V.P. Serbsky National Medical Research Center of Psychiatry and Narcology” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation

S.N. Shikhov

Moscow Research Institute of Psychiatry ‒ Branch of FSBI “V.P. Serbsky National Medical Research Center of Psychiatry and Narcology” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation

V.V. Kryukov

Moscow Research Institute of Psychiatry ‒ Branch of FSBI “V.P. Serbsky National Medical Research Center of Psychiatry and Narcology” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation

V.N. Krasnov

Moscow Research Institute of Psychiatry ‒ Branch of FSBI “V.P. Serbsky National Medical Research Center of Psychiatry and Narcology” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation

 

https://doi.org/10.26617/1810-3111-2025-2(127)-5-14

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 2 (127):  5-14.

 

Abstract

Background. The study of pathogenetic mechanisms of depression, as well as the prediction and implementation of principles of effective therapy for this disease are of primary importance. Brain-derived neurotrophic factor (BDNF) is considered to be one of the key components of pathogenetic mechanisms of depressive disorders. Objective: to determine the BDNF level in the blood serum of patients with melancholic depression under antidepressant therapy. Materials.The sample included patients diagnosed with the current episode of mild or moderate depression (F31.3). According to ICD-10 and DSM-5 criteria, this condition is classified as melancholic depression in the structure of bipolar II disorder. The main group (n=54) was predominated by female patients (63% vs 37%). The mean age of patients was 26 years; IQR [22; 37]. The control group consisted of 11 healthy volunteers without a diagnosis of mental disorder, who matched the patients in the main group by gender and age. 21 patients of 54 were examined for BDNF concentration in the blood serum. Methods: clinical-psychopathological, clinical-dynamic, laboratory, mathematical statis-tics. Clinical-psychopathological examination was performed twice: at baseline and during antidepressant therapy (venlafaxine 75-150 mg/day, lamotrigine 125-150 mg/day) by days 28-30. The severity of depression and anxiety was determined using the Hamilton clinical scales. The concentration of BDNF in the serum was determined by ELISA using a reagent kit for quantitative determination (96 determinations) of BDNF by enzyme immunoassay (human brain-derived neurotrophic factor, BDNF, ELISA Kit, Cusabio Technology LLC, US). Results. Despite the revealed improvement in the clinical status of the patients, the normalization of the BDNF level in the blood serum was not established 30 days after the start of therapy when comparing the patients’ parameters at baseline (n=21) and after the treatment (n=8): Me 15.2; IQR [8.2; 34.1] ng/ml serum vs Me 13.35; IQR [9.73; 43.1] ng/ml of serum (p> 0.05), as well as compared with the BDNF level in healthy controls: Me 19.84 (IQR [13.47; 26.32]; n=11) ng/ml. At the same time, a statistically significant (p<0.05) lower concentration of BDNF in the blood serum was found when compared with the control indices (healthy volunteers; n=11): Me 19.84; IQR [13.47; 26.32] ng/ml of serum. Discussion. In patients with melancholic depression, antidepressant therapy had no effect on the BDNF concentration in the blood serum, since the BDNF levels in the blood serum at baseline and after antidepressant therapy were approximately the same, but were statistically significantly lower relative to the indices in healthy volunteers of the control group. Conclusion. The lack of dynamics in the BDNF concentration in the blood serum of patients with melancholic depression at baseline and after antidepressant therapy is explained by dysfunction of the blood-brain barrier. We hypothesize that oxidative stress, dysfunction of the transport protein P-glycoprotein, impaired cortisol metabolism and effect of vascular endothelial growth factor (VEGF) on the secretion of BDNF from brain cells are involved in this pathological process.

 

Keywords: melancholic depression, brain-derived neurotrophic factor, enzyme immunoassay, blood-brain barrier, P-glycoprotein, oxidative stress, vascular endothelial growth factor.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Uzbekov M.G., Shikhov S.N., Kryukov V.V., Krasnov V.N. The influence of antidepressant therapy on the level of brain-derived neurotrophic factor in the blood serum of patients with melancholic depression: a pilot study. Sibirskii Vestnik Psikhiatrii i Narkologii.2025; 2 (127): 5-14. https://doi.org/10.26617/1810-3111-2025-2(127)-5-14

 

REFERENCES

  1. World Health Assembly. Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level, report by the secretariat. World Health Organization. Switzerland, Geneva, 2012. https://iris.who.int/handle/10665/78898.
  2. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx) [Electronic resource]. 2015. URL: https://vizhub.healthdata.org/gbd-results.2015.
  3. Goodwin RD, Dierker LC, Wu M, Galea S, Hoven CW, Weinberger AH. Trends in U.S. Depression prevalence from 2015 to 2020: The widening treatment gap. Am J Prev Med. 2022 Nov;63(5):726-733. https://doi.org/10.1016/j.amepre.2022.05.014. Epub 2022 Sep 19. PMID: 36272761; PMCID: PMC9483000.
  4. Moreno-Agostino D, Wu YT, Daskalopoulou C, Hasan MT, Huisman M, Prina M. Global trends in the prevalence and incidence of depression: a systematic review and meta-analysis. J Affect Disord. 2021 Feb 15;281:235-243. https://doi.org/10.1016/j.jad.2020.12.035. Epub 2020 Dec 9. PMID: 33338841.
  5. Herrman H, Kieling C, McGorry P, Horton R, Sargent J, Patel V. Reducing the global burden of depression: a Lancet-World Psychiatric Association Commission. Lancet. 2019 Jun 15;393(10189):e42-e43. https://doi.org/10.1016/S0140-6736(18)32408-5. Epub 2018 Oct 25. PMID: 30482607.
  6. Krasnov VN. Problems of current diagnosis of depression. S.S. Korsakov Journal of Neurology and Psychiatry. Special issues. 2012;112 (11-2):3-10 (in Russian).
  7. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: Challenges and strategies. Neuropsychiatr Dis Treat. 2020 Jan 21;16:221-234. https://doi.org/10.2147/NDT.S198774. PMID: 32021216; PMCID: PMC6982454.
  8. Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007 Nov;17(11):696-707. https://doi.org/10.1016/j.euroneuro.2007.03.009. Epub 2007 May 23. PMID: 17521891.
  9. Jarończyk M, Walory J. Novel molecular targets of antidepressants. Molecules. 2022 Jan 14;27(2):533. https://doi.org/10.3390/molecules27020533. PMID: 35056845; PMCID: PMC8778443.
  10. Lima Giacobbo B, Doorduin J, Klein HC, Dierckx RAJO, Bromberg E, de Vries EFJ. Brain-derived neurotrophic factor in brain disorders: Focus on neuroinflammation. Mol Neurobiol. 2019 May;56(5):3295-3312. https://doi.org/10.1007/s12035-018-1283-6. Epub 2018 Aug 17. PMID: 30117106; PMCID: PMC6476855.
  11. Gelle T, Samey RA, Plansont B, Bessette B, Jauberteau-Marchan MO, Lalloué F, Girard M. BDNF and pro-BDNF in serum and exosomes in major depression: Evolution after antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110229. https://doi.org/10.1016/j.pnpbp.2020.110229.Epub 2020 Dec 31. PMID: 33358963.
  12. Chiou YJ, Huang TL. Brain-derived neurotrophic factor (BDNF) and bipolar disorder. Psychiatry Res. 2019 Apr;274:395-399. https://doi.org/10.1016/j.psychres.2019.02.051. Epub 2019 Feb 20. PMID: 30852433.
  13. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res. 2007 Dec;41(12):979-90. https://doi.org/10.1016/j.jpsychires.2006.09.009. Epub 2007 Jan 18. PMID: 17239400.
  14. Noble EE, Billington CJ, Kotz CM, Wang C. The lighter side of BDNF. Am J Physiol Regul Integr Comp Physiol. 2011 May;300(5):R1053-69. https://doi.org/10.1152/ajpregu.00776.2010. Epub 2011 Feb 23. PMID: 21346243; PMCID: PMC3293512.
  15. Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci. 2005 Aug;8(8):1069-77. https://doi.org/10.1038/nn1510. Epub 2005 Jul 17. PMID: 16025106.
  16. Levchuk LA, Meeder EMG, Roschina OV, Loonen AJM, Boiko AS, Michalitskaya EV, Epimakhova EV, Losenkov IS, Simutkin GG, Bokhan NA, Schellekens AFA, Ivanova SA. Exploring brain derived neurotrophic factor and cell adhesion molecules as biomarkers for the transdiagnostic symptom anhedonia in alcohol use disorder and comorbid depression. Front Psychiatry. 2020 Apr 20;11:296. https://doi.org/10.3389/fpsyt.2020.00296. PMID: 32372985; PMCID: PMC7184244.
  17. Ochi T, Vyalova NM, Losenkov IS, Levchuk LA, Osmanova DZ, Mikhalitskaya EV, Loonen AJM, Bosker FJ, Simutkin GG, Bokhan NA, Wilffert B, Ivanova SA. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients. J Affect Disord. 2019 Dec 1;259:432-439. https://doi.org/10.1016/j.jad.2019.08.058. Epub 2019 Aug 21. PMID: 31611000.
  18. Nikolac Perkovic M, Gredicak M, Sagud M, Nedic Erjavec G, Uzun S, Pivac N. The association of brain-derived neurotrophic factor with the diagnosis and treatment response in depression. Expert Rev Mol Diagn. 2023 Apr;23(4):283-296. https://doi.org/10.1080/14737159.2023.2200937. Epub 2023 Apr 14. PMID: 37038358.
  19. Mondal AC, Fatima M. Direct and indirect evidences of BDNF and NGF as key modulators in depression: role of antidepressants treatment. Int J Neurosci. 2019 Mar; 129 (3):283-296. https://doi.org/10.1080/00207454.2018.1527328. Epub 2018 Nov 27. PMID: 30235967.
  20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. https://doi.org/10.1136/jnnp.23.1.56. PMID: 14399272; PMCID: PMC495331.
  21. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x.PMID: 13638508.
  22. International statistical classification of diseases and related health problems. 10th revision. Fifth edition. Geneva, Switzerland, 2016. 3 v.
  23. Criteria for Melancholic Features Specifiers. In: Diagnostic and Statistical Manual of Mental Disorders. Fifth ed. Section II Diagnostic Criteria and Codes. American Psychiatric Association, Washington, USA, 2013.
  24. Kotan Z, Sarandöl E, Kırhan E, Ozkaya G, Kırlı S. Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features. Ther Adv Psychopharmacol. 2012 Apr;2(2):65-74. https://doi.org/10.1177/2045125312436572. PMID: 23983958; PMCID: PMC3736932.
  25. Morris G, Fernandes BS, Puri BK, Walker AJ, Carvalho AF, Berk M. Leaky brain in neurological and psychiatric disorders: Drivers and consequences. Aust N Z J Psychiatry. 2018 Oct;52(10):924-948. https://doi.org/10.1177/0004867418796955. PMID: 30231628.
  26. Mossel P, Arif WM, De Souza GS, Varela LG, van der Weijden CWJ, Boersma HH, Willemsen ATM, Boellaard R, Elsinga PH, Borra RJH, Dierckx RAJO, Lammertsma AA, Bartels AL, Luurtsema G. Quantification of P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):3917-3927. https://doi.org/10.1007/s00259-023-06363-5. PMID: 37552369; PMCID: PMC10611838.
  27. Uzbekov MG. Oxidative stress: the problems of the pathogenesis. Social and Clinical Psychiatry. 2022;32(3):73-82 (in Russian).
  28. Uzbekov MG. Monoamine oxidase as a potential biomarker of the efficacy of treatment of mental disorders. Biochemistry (Mosc). 2021 Jun;86(6):773-783. https://doi.org/10.1134/S0006297921060146. PMID: 34225599.
  29. Hoshi Y, Uchida Y, Tachikawa M, Ohtsuki S, Couraud PO, Suzuki T, Terasaki T. Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood-brain barrier. J Cereb Blood Flow Metab. 2020 Feb;40(2):420-436. https://doi.org/10.1177/0271678X18822801. PMID: 30621530; PMCID: PMC7370610.
  30. Uzbekov MG, Maximova NM. Monoamine-hormonal interactions in the pathogenesis of anxious depression. S.S. Korsakov Journal of Neurology and Psychiatry. Special issues. 2015;115(1 Pt 2):52-55. https://doi.org/10.17116/jnevro20151151252-55. PMID: 25909807 (in Russian).
  31. Gorobets LN, Bulanov VS, Litvinov AV. Dynamics of the levels of cortisol and dehydroepiandrosterone-sulfate in patients with affective disorders in dynamics of venlafaxine therapy. Modern achievements in psychoneuroendocrinology: from theory to practice / Gorobets LN, Dorovskikh IV. (eds.). 2-nd ed. Podolsk, 2022:226-234 (in Russian).
  32. Uzbekov MG, Smolina NV, Syrejshchikova TI, Brilliantova VV, Dobretsov GE, Shikhov SN. Investigation of serum albumin conformational changes in melancholic depression under pharmacotherapy using subnanosecond fluorescent spectroscopy. Neurochem J. 2022;16:480-484. https://doi.org/10.1134/S1819712422040213.
  33. Brilliantova VV, Smolina NV, Syrejshchikova TI, Uzbekov MG, Dobretsov GE. The state of albumin thiol groups in patients with the first episode of schizophrenia. Neurochem J. 2018;12:107-110. https://doi.org/10.1134/S1819712418010038.
  34. Deyama S, Bang E, Kato T, Li XY, Duman RS. Neurotrophic and antidepressant actions of brain-derived neurotrophic factor require vascular endothelial growth factor. Biol Psychiatry. 2019 Jul 15;86(2):143-152. https://doi.org/10.1016/j.biopsych.2018.12.014. Epub 2018 Dec 27. PMID: 30712809; PMCID: PMC6597338.
  35. Fournier NM, Duman RS. Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res. 2012 Feb 14;227(2):440-9. https://doi.org/10.1016/j.bbr.2011.04.022. Epub 2011 Apr 22. PMID: 21536078; PMCID: PMC3176958.
  36. Sharma AN, da Costa e Silva BF, Soares JC, Carvalho AF, Quevedo J. Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies. J Affect Disord. 2016 Jun;197:9-20. https://doi.org/10.1016/j.jad.2016.02.067. Epub 2016 Mar 2. PMID: 26956384; PMCID: PMC4837031.